Project Grant R00HL177829
Award Date
4/21/25
Completion Date
3/31/28
Dollars Obligated
$380K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award, valued at $1,419,308 and spanning from September 2024 to August 2025, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to investigate the mechanisms linking persistent DNA damage to the upregulation of the NLRP12 gene, and the functional implications of this link in aging hematopoiesis. The research aims to establish a novel interplay between persistent DNA...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,085 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to Case Western Reserve University. The grant, which runs from December 5, 2024 to November 30, 2028, aims to investigate how modulating the Heat Shock Transcription Factor 1 (HSF1) protein can sustain or enhance the self-renewal and balanced lineage commitment of hematopoietic stem/progenitor cells, while preventing the progression...
The federal Project Grant award F31HL178296, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research focused on understanding how co-occurring mutations in the DDX41 and CUX1 genes contribute to the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The $161,922 award, with a performance period from July 2025 to March 2028, will enable the researcher to use zebrafish and...
The $814,209 federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel nanoparticle-based gene therapy approach for in vivo hematopoietic stem cell (HSC) modification. The project aims to optimize nanoparticle formulations that can deliver next-generation gene-editing agents and target the HSC-enriched cell population identified in the researchers' prior...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to better understand the signaling and metabolic processes that allow hematopoietic stem cells (HSCs) to self-renew and avoid oxidative damage under hypoxic conditions in the bone marrow. The central goal is to explore methods to manipulate these processes in normoxic conditions in order to improve the functionality of HSCs for...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $749,769 to The Johns Hopkins University to study the factors underlying the failure of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) to fully mature. The research aims to identify a critical gene regulatory network driving this premature maturation arrest, with the goal of developing a transcriptome-based strategy to...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to gain a mechanistic understanding of erythroid progenitor self-renewal, both in vitro and in vivo. The goal is to expand erythroid progenitors to maintain steady-state erythropoiesis and respond to acute anemic or hypoxic stress. The research, conducted by the University of Rochester, focuses on how the chromatin modulators BMI1 and RING1B...
This $642,754.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to understand the mechanisms behind hematopoietic stem cell (HSC) functional decline after bone marrow transplantation. The key objectives are to: 1) investigate why abnormal mitochondria in HSCs are not removed after transplantation and the impact on HSC functions, and 2) explore the effects of mitochondrial defects on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $773,257 to St. Jude Children's Research Hospital to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research project aims to identify factors regulating lysosome segregation during HSC division and examine how the RhoGTPases CDC42 and RAC influence...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,158,000.00 to The Leland Stanford Junior University to develop chemical tools for modulating the fetal hemoglobin inducer BCL11A. The goal is to advance first-in-class protein degraders that can deplete BCL11A, leading to significant induction of fetal hemoglobin, which may provide a curative treatment for sickle cell disease...